MC-GGFG-AM- (10Me-11F-Camptothecin)

MC-GGFG-AM- (10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG) -aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells[1].

Product Specifications

CAS Number

[2873460-70-7]

UNSPSC

12352005

Target

Drug-Linker Conjugates for ADC; Topoisomerase

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mc-ggfg-am-10me-11f-camptothecin.html

Purity

98.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=C(C)C=C2C(CNC(OCCOCNC(CNC([C@H](CC3=CC=CC=C3)NC(CNC(CNC(CCCCCN4C(C=CC4=O)=O)=O)=O)=O)=O)=O)=O)=C5C(C(N6C5)=CC([C@@](O)(CC)C(OC7)=O)=C7C6=O)=NC2=C1

Molecular Formula

C51H56FN9O14

Molecular Weight

1038.04

References & Citations

[1]Madera L, et al. ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload[J]. Cancer Research, 2023, 83 (7_Supplement) : 2658-2658.